An expert oncologist stated that if the drug is approved, he would not use it broadly. He would reserve it for a highly selective niche of high-risk patients who fail initial therapies and have specific NGS biomarkers. This signals a potential disconnect between a formal approval and real-world clinical utility.
A potential unstated argument for approving capivasertib, despite its borderline data, was the fear that a rejection would kill the entire field of AKT inhibitors. This suggests that broader strategic concerns about fostering innovation can sometimes influence regulatory recommendations more than a single drug's specific risk-benefit profile.
The advisory panel rationalized approving a drug with 60% grade 3 toxicity by calling the side effects "manageable." This common industry term can downplay the significant, long-term clinical burden on patients—like insulin-requiring diabetes—especially when the drug's efficacy benefit is not overwhelming or life-extending.
The drug is already approved in breast cancer with a stronger PFS benefit (HR 0.5-0.6) and lower toxicity. Its weaker data in prostate cancer (HR 0.81, 60% grade 3 toxicity) demonstrates that the same drug faces a much higher regulatory bar when the benefit-risk calculation is less favorable in a new disease context.
The FDA's decision to call an ODAC meeting for a trial that met its primary endpoint is a strong signal of agency concern. It indicates significant reservations about the drug's overall benefit-risk profile, particularly the modest efficacy, high toxicity, and lack of an overwhelming survival advantage.